MSB 2.10% $1.17 mesoblast limited

Cell Therapy News/Articles, page-16861

  1. 15,455 Posts.
    lightbulb Created with Sketch. 5535

    THI collaboration receives NIDDK funding for IBD research from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - previously they also received NIH funding for their phase 1 study ... I wonder if our IBD results in the coming months will seek funding from organisations such as these or will we go straight for a license deal ?


    https://www.texasheart.org/the-texa...harmaceuticals-inc-to-develop-novel-ibd-drug/


    The Texas Heart Institute Collaborates with Aviara Pharmaceuticals, Inc. to Develop Novel IBD Drug



    HOUSTON (Sept. 26, 2023) — Aviara Pharmaceuticals, Inc., through a research collaboration with The Texas Heart Institute® (THI), recently was awarded a two-year, $1.9 million grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to develop a safe and novel drug for inflammatory bowel disease (IBD).




 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.17
Change
-0.025(2.10%)
Mkt cap ! $1.324B
Open High Low Value Volume
$1.18 $1.22 $1.15 $5.423M 4.612M

Buyers (Bids)

No. Vol. Price($)
54 68379 $1.16
 

Sellers (Offers)

Price($) Vol. No.
$1.17 23722 9
View Market Depth
Last trade - 15.36pm 15/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.